Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 2503 in advanced colorectal cancer
NCT00004193Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 1999
- Primary completion
- Nov 2000
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of H-Ras antisense oligodeoxynucleotide ISIS 2503 in colorectal cancer (CRC), sponsored by University of Alabama at Birmingham. Primary endpoints: Response Rate, Duration of Response and 1 more. Started Jan 1999; status: terminated.
02
Drugs
H-Ras antisense oligodeoxynucleotide ISIS 2503
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00004193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004193.